| First Author | Machhi J | Year | 2021 |
| Journal | J Neuroinflammation | Volume | 18 |
| Issue | 1 | Pages | 272 |
| PubMed ID | 34798897 | Mgi Jnum | J:322027 |
| Mgi Id | MGI:6826647 | Doi | 10.1186/s12974-021-02308-7 |
| Citation | Machhi J, et al. (2021) CD4+ effector T cells accelerate Alzheimer's disease in mice. J Neuroinflammation 18(1):272 |
| abstractText | BACKGROUND: Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by pathological deposition of misfolded self-protein amyloid beta (Abeta) which in kind facilitates tau aggregation and neurodegeneration. Neuroinflammation is accepted as a key disease driver caused by innate microglia activation. Recently, adaptive immune alterations have been uncovered that begin early and persist throughout the disease. How these occur and whether they can be harnessed to halt disease progress is unclear. We propose that self-antigens would induct autoreactive effector T cells (Teffs) that drive pro-inflammatory and neurodestructive immunity leading to cognitive impairments. Here, we investigated the role of effector immunity and how it could affect cellular-level disease pathobiology in an AD animal model. METHODS: In this report, we developed and characterized cloned lines of amyloid beta (Abeta) reactive type 1 T helper (Th1) and type 17 Th (Th17) cells to study their role in AD pathogenesis. The cellular phenotype and antigen-specificity of Abeta-specific Th1 and Th17 clones were confirmed using flow cytometry, immunoblot staining and Abeta T cell epitope loaded haplotype-matched major histocompatibility complex II IA(b) (MHCII-IA(b)-KLVFFAEDVGSNKGA) tetramer binding. Abeta-Th1 and Abeta-Th17 clones were adoptively transferred into APP/PS1 double-transgenic mice expressing chimeric mouse/human amyloid precursor protein and mutant human presenilin 1, and the mice were assessed for memory impairments. Finally, blood, spleen, lymph nodes and brain were harvested for immunological, biochemical, and histological analyses. RESULTS: The propagated Abeta-Th1 and Abeta-Th17 clones were confirmed stable and long-lived. Treatment of APP/PS1 mice with Abeta reactive Teffs accelerated memory impairment and systemic inflammation, increased amyloid burden, elevated microglia activation, and exacerbated neuroinflammation. Both Th1 and Th17 Abeta-reactive Teffs progressed AD pathology by downregulating anti-inflammatory and immunosuppressive regulatory T cells (Tregs) as recorded in the periphery and within the central nervous system. CONCLUSIONS: These results underscore an important pathological role for CD4+ Teffs in AD progression. We posit that aberrant disease-associated effector T cell immune responses can be controlled. One solution is by Abeta reactive Tregs. |
